

104 - 9295 198th Street  
Langley BC V1M3J9  
Tel: 604.336.0881  
Email: news@abattis.com



## Abattis Issues Common Shares

Vancouver, BC – September 22, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTBF) (CSE: ATT), announces that today the Company issued 3,303,076 common shares as compensation for services to consultants, directors and employees of the Company for the month ended August 31, 2016 and in respect of prior months outstanding, no legend was required on any of the issued shares.

The Company also announced that it has agreed to issued 1,040,945 common shares as settlement of debts owed by the Company in the amount of \$78,070.73 to various creditors.

### **About Abattis Bioceuticals Corp.**

Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: [www.abattis.com](http://www.abattis.com).

ON BEHALF OF THE BOARD

"Rene David"

Rene David, CFO/COO and interim CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**